...
首页> 外文期刊>Biochemistry >Retinal Degeneration 3 (RD3) Protein Inhibits Catalytic Activity of Retinal Membrane Guanylyl Cyclase (RetGC) and Its Stimulation by Activating Proteins
【24h】

Retinal Degeneration 3 (RD3) Protein Inhibits Catalytic Activity of Retinal Membrane Guanylyl Cyclase (RetGC) and Its Stimulation by Activating Proteins

机译:视网膜变性3(RD3)蛋白抑制视网膜膜鸟苷酰环化酶(RetGC)的催化活性及其激活蛋白的刺激作用

获取原文
获取原文并翻译 | 示例

摘要

Retinal membrane guanylyl cyclase (RetGC) in the outer segments of vertebrate photoreceptors is controlled by guanylyl cyclase activating proteins (GCAPs), responding to light-dependent changes of the intracellular Ca~(2+) concentrations. We present evidence that a different RetGC binding protein, retinal degeneration 3 protein (RD3), is a high-affinity allosteric modulator of the cyclase which inhibits RetGC activity at submicromolar concentrations. It suppresses the basal activity of RetGC in the absence of GCAPs in a noncompetitive manner, and it inhibits the GCAP-stimulated RetGC at low intracellular Ca~(2+) levels. RD3 opposes the allosteric activation of the cyclase by GCAP but does not significantly change Ca~(2+) sensitivity of the GCAP-dependent regulation. We have tested a number of mutations in RD3 implicated in human retinal degenerative disorders and have found that several mutations prevent the stable expression of RD3 in HEK293 cells and decrease the affinity of RD3 for RetGC1. The RD3 mutant lacking the carboxy-terminal half of the protein and associated with Leber congenital amaurosis type 12 (LCA12) is unable to suppress the activity of the RetGC1/GCAP complex Furthermore, the inhibitory activity of the GS7V mutant implicated in cone–rod degeneration is strongly reduced. Our results suggest that inhibition of RetGC by RD3 may be utilized by photoreceptors to block RetGC activity during its maturation and/or incorporation into the photoreceptor outer segment rather than participate in dynamic regulation of the cyclase by Ca~(2+) and GCAPs.
机译:脊椎动物感光细胞外段的视网膜膜鸟嘌呤环化酶(RetGC)受鸟嘌呤环化酶激活蛋白(GCAPs)控制,响应细胞内Ca〜(2+)浓度的光依赖性变化。我们目前的证据表明,不同的RetGC结合蛋白,视网膜变性3蛋白(RD3),是环化酶的高亲和力变构调节剂,可抑制亚微摩尔浓度的RetGC活性。它在不存在GCAP的情况下以非竞争性方式抑制RetGC的基础活性,并且在低细胞内Ca〜(2+)水平下抑制GCAP刺激的RetGC。 RD3反对GCAP对环化酶的变构激活,但不会显着改变GCAP依赖性调节的Ca〜(2+)敏感性。我们已经测试了与人类视网膜变性疾病有关的RD3突变,并发现一些突变阻止了HEK293细胞中RD3的稳定表达并降低了RD3对RetGC1的亲和力。 RD3突变体缺少蛋白质的羧基末端一半,并且与Leber先天性黑度12型(LCA12)相关,无法抑制RetGC1 / GCAP复合物的活性。此外,GS7V突变体的抑制活性与锥杆变性有关大大减少。我们的研究结果表明,RD3对RetGC的抑制作用可被感光器用来在其成熟和/或掺入感光器外部片段时阻断RetGC的活性,而不是通过Ca〜(2+)和GCAP参与环化酶的动态调节。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号